company background image
PAHC

Phibro Animal HealthNasdaqGM:PAHC Stock Report

Market Cap

US$845.7m

7D

-4.2%

1Y

7.5%

Updated

26 Nov, 2021

Data

Company Financials +
PAHC fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance3/6
Financial Health4/6
Dividends3/6

PAHC Stock Overview

Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States.

Phibro Animal Health Competitors

Merck

NYSE:MRK

US$200.0b

Zoetis

NYSE:ZTS

US$103.8b

Elanco Animal Health

NYSE:ELAN

US$14.3b

Parnell Pharmaceuticals Holdings

OTCPK:PARN.F

US$3.0k

Price History & Performance

Summary of all time highs, changes and price drops for Phibro Animal Health
Historical stock prices
Current Share PriceUS$20.88
52 Week HighUS$31.00
52 Week LowUS$17.70
Beta0.56
1 Month Change-4.83%
3 Month Change-10.92%
1 Year Change7.46%
3 Year Change-38.41%
5 Year Change-21.80%
Change since IPO22.82%

Recent News & Updates

Nov 05
Phibro Animal Health (NASDAQ:PAHC) Has Re-Affirmed Its Dividend Of US$0.12

Phibro Animal Health (NASDAQ:PAHC) Has Re-Affirmed Its Dividend Of US$0.12

Phibro Animal Health Corporation ( NASDAQ:PAHC ) has announced that it will pay a dividend of US$0.12 per share on the...

Oct 26
We Discuss Why Phibro Animal Health Corporation's (NASDAQ:PAHC) CEO Compensation May Be Closely Reviewed

We Discuss Why Phibro Animal Health Corporation's (NASDAQ:PAHC) CEO Compensation May Be Closely Reviewed

Shareholders will probably not be too impressed with the underwhelming results at Phibro Animal Health Corporation...

Shareholder Returns

PAHCUS PharmaceuticalsUS Market
7D-4.2%-0.5%-2.7%
1Y7.5%17.7%21.3%

Return vs Industry: PAHC underperformed the US Pharmaceuticals industry which returned 17.7% over the past year.

Return vs Market: PAHC underperformed the US Market which returned 21.3% over the past year.

Price Volatility

Is PAHC's price volatile compared to industry and market?
PAHC volatility
PAHC Average Weekly Movement4.3%
Pharmaceuticals Industry Average Movement9.3%
Market Average Movement5.9%
10% most volatile stocks in US Market15.1%
10% least volatile stocks in US Market2.2%

Stable Share Price: PAHC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: PAHC's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19461,725Jack Bendheimhttps://www.pahc.com

Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture.

Phibro Animal Health Fundamentals Summary

How do Phibro Animal Health's earnings and revenue compare to its market cap?
PAHC fundamental statistics
Market CapUS$845.72m
Earnings (TTM)US$48.62m
Revenue (TTM)US$852.82m

17.4x

P/E Ratio

1.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PAHC income statement (TTM)
RevenueUS$852.82m
Cost of RevenueUS$580.89m
Gross ProfitUS$271.94m
ExpensesUS$223.32m
EarningsUS$48.62m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)1.20
Gross Margin31.89%
Net Profit Margin5.70%
Debt/Equity Ratio174.9%

How did PAHC perform over the long term?

See historical performance and comparison

Dividends

2.3%

Current Dividend Yield

40%

Payout Ratio

Valuation

Is Phibro Animal Health undervalued compared to its fair value and its price relative to the market?

17.4x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: PAHC ($20.88) is trading above our estimate of fair value ($13.7)

Significantly Below Fair Value: PAHC is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: PAHC is good value based on its PE Ratio (17.4x) compared to the US Pharmaceuticals industry average (23.4x).

PE vs Market: PAHC is poor value based on its PE Ratio (17.4x) compared to the US market (17.2x).


Price to Earnings Growth Ratio

PEG Ratio: PAHC's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: PAHC is overvalued based on its PB Ratio (3.6x) compared to the US Pharmaceuticals industry average (2.7x).


Future Growth

How is Phibro Animal Health forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-3.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PAHC's earnings are forecast to decline over the next 3 years (-3.4% per year).

Earnings vs Market: PAHC's earnings are forecast to decline over the next 3 years (-3.4% per year).

High Growth Earnings: PAHC's earnings are forecast to decline over the next 3 years.

Revenue vs Market: PAHC's revenue (3.3% per year) is forecast to grow slower than the US market (10.1% per year).

High Growth Revenue: PAHC's revenue (3.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PAHC's Return on Equity is forecast to be low in 3 years time (19.7%).


Past Performance

How has Phibro Animal Health performed over the past 5 years?

-10.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PAHC has high quality earnings.

Growing Profit Margin: PAHC's current net profit margins (5.7%) are higher than last year (5.4%).


Past Earnings Growth Analysis

Earnings Trend: PAHC's earnings have declined by 10.9% per year over the past 5 years.

Accelerating Growth: PAHC's earnings growth over the past year (12.2%) exceeds its 5-year average (-10.9% per year).

Earnings vs Industry: PAHC earnings growth over the past year (12.2%) underperformed the Pharmaceuticals industry 12.2%.


Return on Equity

High ROE: Whilst PAHC's Return on Equity (20.84%) is high, this metric is skewed due to their high level of debt.


Financial Health

How is Phibro Animal Health's financial position?


Financial Position Analysis

Short Term Liabilities: PAHC's short term assets ($498.6M) exceed its short term liabilities ($152.6M).

Long Term Liabilities: PAHC's short term assets ($498.6M) exceed its long term liabilities ($450.2M).


Debt to Equity History and Analysis

Debt Level: PAHC's net debt to equity ratio (133.3%) is considered high.

Reducing Debt: PAHC's debt to equity ratio has reduced from 334.5% to 174.9% over the past 5 years.

Debt Coverage: PAHC's debt is not well covered by operating cash flow (12.4%).

Interest Coverage: PAHC's interest payments on its debt are well covered by EBIT (5.7x coverage).


Balance Sheet


Dividend

What is Phibro Animal Health current dividend yield, its reliability and sustainability?

2.30%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: PAHC's dividend (2.3%) is higher than the bottom 25% of dividend payers in the US market (1.32%).

High Dividend: PAHC's dividend (2.3%) is low compared to the top 25% of dividend payers in the US market (3.58%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, PAHC has been paying a dividend for less than 10 years.

Growing Dividend: PAHC's dividend payments have increased, but the company has only paid a dividend for 7 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (40%), PAHC's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: PAHC's dividends in 3 years are forecast to be well covered by earnings (36.9% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.0yrs

Average management tenure


CEO

Jack Bendheim (74 yo)

7.67yrs

Tenure

US$4,001,319

Compensation

Mr. Jack Clifford Bendheim has been the President and Chief Executive Officer of Phibro Animal Health Corporation since 1988 and March 2014, respectively and serves as its Chairman. Mr. Bendheim served as...


CEO Compensation Analysis

Compensation vs Market: Jack's total compensation ($USD4.00M) is above average for companies of similar size in the US market ($USD2.26M).

Compensation vs Earnings: Jack's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: PAHC's management team is seasoned and experienced (5 years average tenure).


Board Members

Experienced Board: PAHC's board of directors are seasoned and experienced ( 13.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PAHC insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Phibro Animal Health Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Phibro Animal Health Corporation
  • Ticker: PAHC
  • Exchange: NasdaqGM
  • Founded: 1946
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$845.715m
  • Shares outstanding: 40.50m
  • Website: https://www.pahc.com

Number of Employees


Location

  • Phibro Animal Health Corporation
  • Glenpointe Centre East
  • 3rd Floor
  • Teaneck
  • New Jersey
  • 07666-6712
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/26 23:17
End of Day Share Price2021/11/26 00:00
Earnings2021/09/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.